Breast Cancer: Early Detection, Symptoms, and Treatment Approaches

Breast cancer is the most frequently diagnosed cancer among women globally, with approximately 2.3 million new cases each year. Despite its prevalence, advances in screening, molecular profiling, and targeted therapy have transformed outcomes dramatically — the five-year survival rate for localised breast cancer now exceeds 99% in many countries. Understanding risk, detecting disease early, and navigating a complex treatment landscape are three essential steps every person should be empowered to take.

Types of Breast Cancer

Most breast cancers originate in the milk ducts (ductal carcinoma) or lobules (lobular carcinoma). When cancer cells remain confined within these structures it is classified as in situ (non-invasive); when cells breach the basement membrane it becomes invasive. Receptor status — oestrogen receptor (ER), progesterone receptor (PR), and HER2 — determines which therapies will be effective and profoundly influences prognosis. Hormone receptor-positive (HR+) cancers represent approximately 70% of cases and respond to endocrine therapy. HER2-positive cancers are driven by overexpression of a growth-promoting protein and respond to targeted antibody therapies. Triple-negative breast cancer (TNBC) — lacking all three receptors — is more aggressive and relies predominantly on chemotherapy and emerging immunotherapy.

Risk Factors

Non-Modifiable Factors

• Age and Sex: Being female is the dominant risk factor. Risk rises progressively after 40; about two-thirds of invasive cancers occur in women aged 55 and older.
• BRCA1/BRCA2 Mutations: These inherited mutations confer a lifetime breast cancer risk of 50–72%. Testing is recommended for individuals with a strong personal or family history, male breast cancer in the family, or Ashkenazi Jewish ancestry.
• Family History: A first-degree relative with breast cancer roughly doubles personal risk; multiple affected relatives or early-onset disease in the family increase it further.
• Dense Breast Tissue: Women with dense breasts have four to six times higher risk than those with predominantly fatty tissue and receive less accurate mammography — a combination that underscores the value of supplemental ultrasound or MRI screening.
• Prior Breast Conditions: Atypical ductal or lobular hyperplasia raises future risk four to five-fold.

Modifiable Factors

• Alcohol: Even one drink per day is associated with a 7–10% increase in risk. The relationship is linear — risk rises with each additional drink consumed.
• Post-menopausal Obesity: Adipose tissue becomes the primary oestrogen source after menopause. Excess body fat elevates circulating oestrogen, promoting HR+ cancer growth.
• Physical Inactivity: Regular exercise reduces breast cancer risk by 10–20% through effects on hormonal levels, immune function, and insulin resistance.
• Combined Hormone Therapy: Long-term use (≥5 years) of combined oestrogen-progestogen HRT modestly increases risk. Oestrogen-only therapy in women who have had a hysterectomy carries less risk.

Early Detection

Mammography

Screening mammography reduces breast cancer mortality by 15–20%. Recommendations vary: the American Cancer Society recommends annual screening from age 40; the US Preventive Services Task Force recommends biennial screening from 50–74. Women at high genetic risk (BRCA carriers, prior chest radiation) should discuss annual breast MRI starting at age 25–30 with their physician. Digital breast tomosynthesis (3D mammography) offers superior sensitivity, particularly in dense breast tissue, and is increasingly the standard of care.

Breast Self-Awareness

Monthly formal self-examination is no longer universally mandated, but knowing how your breasts normally look and feel is invaluable. Promptly report any new lump, skin dimpling, nipple retraction or bloody discharge, persistent asymmetry, or redness to a healthcare provider. Most breast cancers are painless at presentation.

Symptoms

Early breast cancer typically produces no symptoms — reinforcing the necessity of screening. As disease advances: a hard or soft lump in the breast or armpit; skin dimpling (peau d'orange texture); nipple inversion or bloody discharge; persistent redness, scaling, or thickening of the nipple or breast skin; or changes in breast shape or size all warrant evaluation.

Diagnosis

Abnormal screening findings trigger diagnostic mammography, targeted ultrasound, and — critically — core needle biopsy guided by imaging. Biopsy provides tissue for histological analysis and receptor profiling (ER, PR, HER2 status). Genomic tests such as Oncotype DX and MammaPrint analyse tumour gene expression to predict recurrence risk and guide chemotherapy decisions in HR+ disease, sparing many women unnecessary treatment. Staging integrates tumour size, lymph node status, metastases, grade, and molecular subtypes.

Treatment Options

Surgery

Breast-conserving surgery (lumpectomy) removes the tumour with clear margins and is equivalent to mastectomy in survival when followed by radiation. Mastectomy — unilateral or prophylactic bilateral — is appropriate for larger tumours, multiple tumour foci, BRCA mutation carriers, or patient preference. Sentinel lymph node biopsy evaluates axillary nodal status with minimal morbidity.

Radiation

Post-lumpectomy radiation reduces local recurrence risk by approximately two-thirds. Modern intensity-modulated techniques and hypofractionated regimens (delivering higher doses over fewer sessions) achieve equivalent outcomes with reduced toxicity and inconvenience.

Systemic Therapies

• Endocrine Therapy: Tamoxifen (pre-menopausal women) and aromatase inhibitors — anastrozole, letrozole, exemestane (post-menopausal women) — substantially reduce recurrence in HR+ disease. Extended therapy for 10 years provides additional protection for high-risk patients.
• Targeted HER2 Therapy: Trastuzumab (Herceptin) and pertuzumab in combination have dramatically improved survival in HER2+ disease. Antibody-drug conjugate trastuzumab deruxtecan (T-DXd) produces remarkable responses in metastatic HER2-low disease.
• Chemotherapy: Anthracycline-taxane regimens are standard for TNBC, high-risk HR+, and HER2+ cancers. Neoadjuvant chemotherapy (before surgery) can downstage tumours and provides important prognostic information through pathological response assessment.
• Immunotherapy: Pembrolizumab combined with chemotherapy is approved for PD-L1-positive TNBC in both early-stage neoadjuvant and metastatic settings, producing meaningful survival gains.
• CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib combined with endocrine therapy have substantially prolonged progression-free and overall survival in metastatic HR+ disease.
• PARP Inhibitors: Olaparib and talazoparib exploit impaired DNA repair in BRCA-mutated cancers and are approved for both early-stage (adjuvant) and metastatic settings.

Survivorship

Survivorship care encompasses ongoing surveillance (annual mammography, regular examination), management of treatment side effects (bone health with aromatase inhibitors, lymphoedema after axillary surgery), and psychological support. Exercise during and after treatment reduces fatigue and improves quality of life. Evidence increasingly supports post-treatment physical activity as a modifier of recurrence risk, particularly in HR+ disease. Reconstruction options after mastectomy have expanded considerably; decisions should be made through thorough shared decision-making before surgery.

Frequently Asked Questions

Do men get breast cancer?

Yes — male breast cancer accounts for about 1% of all cases. Risk factors include BRCA2 mutations, Klinefelter syndrome, obesity, and elevated oestrogen levels. Men are frequently diagnosed at later stages due to lower awareness, but stage-for-stage prognosis is comparable to women.

Is every breast lump cancerous?

No. The majority of breast lumps are benign — fibroadenomas, cysts, or fibrocystic changes are common. However, any new or changing lump deserves prompt medical evaluation. Only biopsy can definitively rule out malignancy.

Does breastfeeding reduce risk?

Yes. Cumulative breastfeeding for ≥12 months is associated with approximately 4% risk reduction per year of breastfeeding, with additional benefit per birth. The mechanism involves delayed resumption of menstrual cycles and differentiation of breast tissue.

How long does treatment last?

Early-stage treatment spans approximately 6–12 months for active therapy (surgery, radiation, and chemotherapy if required), followed by 5–10 years of endocrine therapy for HR+ disease. Long-term surveillance continues for decades.

What is genetic counselling and who should consider it?

Genetic counselling evaluates personal and family history to assess hereditary cancer syndrome probability and guide testing decisions. It is recommended for women with early-onset breast cancer, bilateral disease, ovarian cancer, multiple affected relatives, or male breast cancer in the family. Identifying a BRCA mutation informs both personal management and enables testing of at-risk relatives.

Sources

• World Health Organization. Breast Cancer fact sheet. 2023.
• American Cancer Society. Breast Cancer Facts and Figures 2022–2024.
• Cardoso F, et al. Early breast cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2019.
• NCCN. Breast Cancer Guidelines. Version 2023.
• Mayo Clinic. Breast cancer — Diagnosis and treatment. 2023.